Overview

Beta-Blocker Evaluation in Survival Trial (BEST)

Status:
Completed

Trial end date:
1999-09-01

Target enrollment:
0

Participant gender:
All

Summary

To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Adrenergic Agents
Adrenergic beta-Antagonists

Criteria

Men and women, ages 18 and over. Patients had compensated congestive heart failure due to
idiopathic dilated cardiomyopathy or coronary disease with ejection fraction less than or
equal to 0.35, were in the New York Heart Association functional class III or IV, and were
taking an angiotensin-converting enzyme inhibitor, digitalis, and if needed, a diuretic.
Patients with a specific indication for, or contraindication to, beta-blockade were
excluded.